Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00351728
Recruitment Status : Completed
First Posted : July 13, 2006
Last Update Posted : July 7, 2016
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:
Patients diagnosed with ocular melanoma consent to participate in the study. Combined PET/CT scans of the whole body are performed at baseline, three months later, and six months after that for a total of three combined scans in the first year. Subsequently, these combined scans will be performed at 6-monthly intervals for a total of two combined scans per year.

Condition or disease
Ocular Melanoma Choroidal Melanoma Uveal Melanoma

Study Type : Observational
Actual Enrollment : 174 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : June 2006
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
choroidal melanoma patients

Inclusion Criteria:

  1. Patients with a diagnosis of ocular melanoma (a pigmented malignant tumor) involving the choroid and/or ciliary body (the blood vessel layer in the back of the eye and/or the part of the eye behind the iris).
  2. Patients 18 years of age or older.
  3. Patients able to give informed consent.

Exclusion Criteria:

  1. Patients who refuse to participate in the study.
  2. Patients who are unable to cooperate with or cannot undergo PET/CT scanning.
  3. Patients who will be moving out of the area of UCLA during the ten years of this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00351728

United States, California
Jules Stein Eye Institute
Los Angeles, California, United States, 90095-7000
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Principal Investigator: Tara A McCannel, MD, PhD Jules Stein Eye Institute, UCLA

Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00351728     History of Changes
Other Study ID Numbers: UCLA IRB #05-04-016
First Posted: July 13, 2006    Key Record Dates
Last Update Posted: July 7, 2016
Last Verified: July 2016

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas